Maxcyte, INC 8-K filings

MaxCyte, Inc. announced that its stockholders approved the election of Class II Directors and ratified the selection of CohnReznick LLP as its independent auditor at the 2026 Annual Meeting.

MaxCyte, Inc. has successfully regained compliance with Nasdaq's minimum bid price requirement, closing the matter of its delisting concerns.

MaxCyte announced its first quarter 2026 financial results, reporting a 7% decrease in total revenue to $9.7 million, while reiterating its full-year revenue guidance and authorizing a $10 million share repurchase program.

MaxCyte, Inc. announced the appointment of Parmeet Ahuja as its new Chief Financial Officer, effective March 30, 2026, succeeding Douglas Swirsky.

MaxCyte announced its fourth quarter and full year 2025 financial results, reporting revenue at the top of its preliminary range but providing lower revenue guidance for 2026 due to customer headwinds.

MaxCyte, Inc. received a notice from Nasdaq regarding non-compliance with the minimum $1.00 bid price requirement, initiating a 180-day compliance period.

MaxCyte announced preliminary unaudited financial results for Q4 and full-year 2025, with core revenue meeting guidance despite a challenging macro environment.

MaxCyte, Inc. announced its third quarter 2025 financial results, reporting a 16% decrease in total revenue to $6.8 million but reiterating its full-year 2025 revenue guidance and highlighting cost reduction efforts.

MaxCyte, Inc. announced preliminary third quarter 2025 financial results, including a 16% total revenue decline, and reiterated its full-year 2025 revenue guidance, while also delaying its earnings call to address accounting matters.

MaxCyte, Inc. announced a significant workforce reduction of approximately 34% globally to streamline operations and accelerate its path to profitability.

MaxCyte, Inc. announced the departure of Chief Commercial Officer Ali Soleymannezhad, detailing his severance package.

MaxCyte, Inc. reported an 18% decrease in total revenue for Q2 2025 and lowered its full-year 2025 guidance due to customer inventory management and pipeline reprioritization.

MaxCyte, Inc. has announced its application to delist its common stock from the AIM market of the London Stock Exchange, effective June 26, 2025, while maintaining its Nasdaq listing.

MaxCyte, Inc. stockholders approved an amendment to the 2022 Equity Incentive Plan, increasing authorized shares by 2.95 million, alongside the cancellation of its AIM market listing and other key proposals at its annual meeting.

MaxCyte announced its Q1 2025 financial results, showing a slight increase in core revenue and reiterating its full-year 2025 guidance.

MaxCyte reports a decrease in total revenue for 2024, but anticipates core revenue growth in 2025 while managing cash reserves.

MaxCyte has acquired SeQure Dx to broaden its cell engineering offerings with on-target and off-target editing assessment services.

MaxCyte reports preliminary unaudited financial results for Q4 and full year 2024, showing core revenue growth and increased cash reserves.

Art Mandell, a long-standing member of MaxCyte's Board of Directors, has announced his retirement effective December 31, 2024, after serving since 2006.

MaxCyte implements a workforce reduction of approximately 15% to streamline operations, while also raising its full-year 2024 core revenue guidance to 6-8% growth.

MaxCyte announced a 2% increase in total revenue and a 23% increase in core business revenue for the third quarter of 2024, alongside updated full-year guidance.

MaxCyte has appointed Cynthia Collins to its Board of Directors, increasing its size to ten members and adding significant expertise in cell therapy and genetic medicine.

MaxCyte's second quarter 2024 revenue increased by 15% year-over-year, primarily due to a significant rise in Strategic Platform License (SPL) revenue, despite a decline in core business revenue.

MaxCyte's stockholders approved an amendment to the 2022 Equity Incentive Plan, increasing the share reserve by 2.3 million shares.

MaxCyte announced a 32% increase in total revenue for the first quarter of 2024, driven by significant growth in its Strategic Platform License program.

MaxCyte's fourth quarter saw a revenue increase driven by its Strategic Platform License program, while full-year results showed a decline in core business revenue.

MaxCyte has provided its 2024 revenue guidance, projecting flat to 5% growth in core revenue and approximately $3 million in SPL program-related revenue, while reaffirming its 2023 preliminary results.

MaxCyte, Inc. has announced the departure of Chief Scientific Officer, Cenk Sumen, effective January 23, 2024, with a severance package and continued advisory role.